SG11201507883SA - Wt1-antigen peptide conjugate vaccine - Google Patents
Wt1-antigen peptide conjugate vaccineInfo
- Publication number
- SG11201507883SA SG11201507883SA SG11201507883SA SG11201507883SA SG11201507883SA SG 11201507883S A SG11201507883S A SG 11201507883SA SG 11201507883S A SG11201507883S A SG 11201507883SA SG 11201507883S A SG11201507883S A SG 11201507883SA SG 11201507883S A SG11201507883S A SG 11201507883SA
- Authority
- SG
- Singapore
- Prior art keywords
- peptide conjugate
- antigen peptide
- conjugate vaccine
- vaccine
- antigen
- Prior art date
Links
- 108010060123 Conjugate Vaccines Proteins 0.000 title 1
- 239000000427 antigen Substances 0.000 title 1
- 229940031670 conjugate vaccine Drugs 0.000 title 1
- 239000000863 peptide conjugate Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001152—Transcription factors, e.g. SOX or c-MYC
- A61K39/001153—Wilms tumor 1 [WT1]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013072173 | 2013-03-29 | ||
| JP2013158383 | 2013-07-31 | ||
| PCT/JP2014/059336 WO2014157692A1 (ja) | 2013-03-29 | 2014-03-28 | Ｗｔ１抗原ペプチドコンジュゲートワクチン |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201507883SA true SG11201507883SA (en) | 2015-10-29 |
Family
ID=51624648
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201507883SA SG11201507883SA (en) | 2013-03-29 | 2014-03-28 | Wt1-antigen peptide conjugate vaccine |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US9181302B2 (ja) |
| EP (2) | EP2982681B8 (ja) |
| JP (4) | JP5885885B2 (ja) |
| KR (1) | KR102121638B1 (ja) |
| CN (1) | CN105308063B (ja) |
| AU (1) | AU2014244860B2 (ja) |
| CA (1) | CA2907782C (ja) |
| DK (1) | DK2982681T3 (ja) |
| ES (1) | ES2691091T3 (ja) |
| HK (1) | HK1220471A1 (ja) |
| IL (1) | IL241566B (ja) |
| MX (1) | MX364459B (ja) |
| MY (1) | MY171854A (ja) |
| NZ (1) | NZ712148A (ja) |
| PH (1) | PH12015502180B1 (ja) |
| RU (1) | RU2668560C2 (ja) |
| SG (1) | SG11201507883SA (ja) |
| TR (1) | TR201816260T4 (ja) |
| TW (1) | TWI666026B (ja) |
| WO (1) | WO2014157692A1 (ja) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2900087C (en) | 2005-10-17 | 2024-02-13 | Sloan Kettering Institute For Cancer Research | Wt1 hla class ii-binding peptides and compositions and methods comprising same |
| EP3117836A1 (en) | 2006-04-10 | 2017-01-18 | Sloan Kettering Institute For Cancer Research | Immunogenic wt-1 peptides and uses thereof |
| WO2013106834A2 (en) | 2012-01-13 | 2013-07-18 | Memorial Sloan Kettering Cancer Center | Immunogenic wt-1 peptides and methods of use thereof |
| KR102208505B1 (ko) | 2012-12-11 | 2021-01-27 | 앨버트 아인슈타인 컬리지 오브 메디신 | 고처리량 수용체:리간드 확인을 위한 방법 |
| PT2945647T (pt) | 2013-01-15 | 2020-11-26 | Memorial Sloan Kettering Cancer Center | Péptidos imunogénicos wt-1 e métodos de uso dos mesmos |
| US10815273B2 (en) | 2013-01-15 | 2020-10-27 | Memorial Sloan Kettering Cancer Center | Immunogenic WT-1 peptides and methods of use thereof |
| JP6671956B2 (ja) * | 2013-03-29 | 2020-03-25 | 大日本住友製薬株式会社 | Ｅｒａｐ１によるトリミング機能をきっかけとしたコンジュゲートワクチン |
| RU2668560C2 (ru) * | 2013-03-29 | 2018-10-02 | Сумитомо Дайниппон Фарма Ко., Лтд. | Конъюгированная вакцина на основе пептида антигена wt1 |
| DK3199175T3 (da) * | 2014-09-27 | 2022-06-13 | Sumitomo Pharma Co Ltd | Farmaceutisk sammensætning til injektion |
| JP6515182B2 (ja) * | 2015-05-20 | 2019-05-15 | 大日本住友製薬株式会社 | Ｗｔ１抗原ペプチドおよび免疫調節剤の併用 |
| MY189596A (en) * | 2015-07-15 | 2022-02-18 | Immatics Biotechnologies Gmbh | A novel peptides for use in immunotherapy against epithelial ovarian cancer and other cancers |
| US11752238B2 (en) | 2016-02-06 | 2023-09-12 | President And Fellows Of Harvard College | Recapitulating the hematopoietic niche to reconstitute immunity |
| EP3458095A4 (en) | 2016-05-18 | 2019-11-27 | Albert Einstein College of Medicine | PD-L1 POLYPEPTIDE VARIANTS, T-LYMPHOCYTE MODULATOR MULTIMERIC POLYPEPTIDES AND METHODS OF USING SAME |
| CN109475628A (zh) | 2016-05-18 | 2019-03-15 | 库尔生物制药有限公司 | T细胞调节性多聚体多肽及其使用方法 |
| US11555177B2 (en) | 2016-07-13 | 2023-01-17 | President And Fellows Of Harvard College | Antigen-presenting cell-mimetic scaffolds and methods for making and using the same |
| CN109415410B (zh) * | 2016-09-21 | 2022-12-13 | 一般财团法人阪大微生物病研究会 | 靶向树突细胞的肽、利用了该肽的肽融合体、及利用了该肽融合体的疫苗 |
| WO2018101309A1 (ja) | 2016-11-30 | 2018-06-07 | 大日本住友製薬株式会社 | Ｗｔ１ヘルパーペプチド及びこれと癌抗原ペプチドコンジュゲート体との組合せ |
| EP3558339B1 (en) | 2016-12-22 | 2024-01-24 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| EP3565829A4 (en) | 2017-01-09 | 2021-01-27 | Cue Biopharma, Inc. | MULTIMER POLYPEPTIDES T-LYMPHOCYTE MODULATORS AND THEIR METHODS OF USE |
| IL309479A (en) | 2017-03-15 | 2024-02-01 | Cue Biopharma Inc | Methods for modulating an immune response |
| WO2018181648A1 (ja) | 2017-03-30 | 2018-10-04 | 大日本住友製薬株式会社 | Ｗｔ１癌抗原ペプチドおよびこれを含むペプチドコンジュゲート体 |
| US20200368338A1 (en) * | 2017-12-27 | 2020-11-26 | Sumitomo Dainippon Pharma Co., Ltd. | Conjugate of wt1-derived peptides and composition comprising the same |
| EP3737689A4 (en) | 2018-01-09 | 2021-12-01 | Cue Biopharma, Inc. | MULTIMERIC T CELL-MODULATING POLYPEPTIDES AND METHOD OF USING THEREOF |
| KR20210068060A (ko) | 2018-09-28 | 2021-06-08 | 다이니뽄 스미토모 세이야쿠 가부시키가이샤 | 주사용 조성물 |
| WO2020071551A1 (ja) | 2018-10-05 | 2020-04-09 | 株式会社癌免疫研究所 | 良性腫瘍の予防または治療薬 |
| TW202045528A (zh) | 2019-02-28 | 2020-12-16 | 日商大日本住友製藥股份有限公司 | 選擇可期待用於治療或預防癌之醫藥組合物之效果之對象之方法 |
| US20220211844A1 (en) | 2019-04-05 | 2022-07-07 | Sumitomo Dainippon Pharma Co., Ltd. | Water soluble adjuvant and composition containing same |
| CN113905758A (zh) | 2019-04-05 | 2022-01-07 | 大日本住友制药株式会社 | 水溶性佐剂和含有其的组合物 |
| KR20220113428A (ko) | 2019-12-10 | 2022-08-12 | 스미토모 파마 가부시키가이샤 | 펩티드 에멀션 제제의 조제 방법 |
| JP2023521219A (ja) * | 2020-04-14 | 2023-05-23 | ウニヴェルシテ ド モントリオール | 急性骨髄性白血病（ａｍｌ）に対する新規の腫瘍特異的抗原及びそれらの使用 |
| KR20230009426A (ko) * | 2020-05-12 | 2023-01-17 | 스미토모 파마 가부시키가이샤 | 암을 처치하기 위한 의약 조성물 |
| CA3169949A1 (en) | 2020-05-12 | 2021-11-18 | Cue Biopharma, Inc. | Multimeric t-cell modulatory polypeptides and methods of use thereof |
| CN111647066B (zh) * | 2020-07-01 | 2020-12-18 | 维肽瀛(上海)生物技术有限公司 | Wt1多肽肿瘤抑制剂 |
| JP2022156071A (ja) | 2021-03-31 | 2022-10-14 | 株式会社小糸製作所 | 画像投影装置 |
| WO2023017836A1 (ja) | 2021-08-12 | 2023-02-16 | 株式会社癌免疫研究所 | 癌を処置または予防するための医薬組成物および方法 |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6410022B1 (en) * | 1995-05-01 | 2002-06-25 | Avant Immunotherapeutics, Inc. | Modulation of cholesteryl ester transfer protein (CETP) activity |
| CA2242878C (en) | 1996-01-24 | 2010-06-22 | Cytel Corporation | Induction of immune response against desired determinants |
| CN1178956C (zh) | 1998-07-31 | 2004-12-08 | 杉山治夫 | 基于癌抑制基因wt1的产物的癌抗原 |
| US20120301492A1 (en) | 1998-09-30 | 2012-11-29 | Corixa Corporation | Compositions and methods for wt1 specific immunotherapy |
| CA2349442C (en) | 1998-09-30 | 2012-12-04 | Corixa Corporation | Compositions and methods for wt1 specific immunotherapy |
| GB9823897D0 (en) | 1998-11-02 | 1998-12-30 | Imp College Innovations Ltd | Immunotherapeutic methods and molecules |
| GB9826143D0 (en) | 1998-11-27 | 1999-01-20 | Ludwig Inst Cancer Res | Tumour rejection antigens |
| JPWO2002047474A1 (ja) | 2000-12-13 | 2004-04-15 | 住友製薬株式会社 | Ｈｌａ−ａ２４発現トランスジェニック動物及びその利用 |
| TWI318630B (en) | 2001-03-22 | 2009-12-21 | Int Inst Cancer Immunology Inc | Wt1 modified peptide |
| AU2003242305A1 (en) | 2002-06-12 | 2003-12-31 | Chugai Seiyaku Kabushiki Kaisha | Hla-a24-restricted cancer antigen peptide |
| US7378384B2 (en) | 2002-09-20 | 2008-05-27 | International Institute Of Cancer Immunology, Inc. | WT1 substitution peptides |
| DE60329115D1 (de) | 2002-09-27 | 2009-10-15 | Dainippon Sumitomo Pharma Co | Tumorantigenprotein und dessen verwendung |
| EP2572715A1 (en) | 2002-12-30 | 2013-03-27 | 3M Innovative Properties Company | Immunostimulatory Combinations |
| WO2004063217A1 (ja) * | 2003-01-15 | 2004-07-29 | Chugai Seiyaku Kabushiki Kaisha | 二量体化ペプチド |
| EP1613308A4 (en) | 2003-03-27 | 2008-02-20 | Lankenau Inst Medical Res | CANCER TREATMENT METHODS |
| US20040197312A1 (en) | 2003-04-02 | 2004-10-07 | Marina Moskalenko | Cytokine-expressing cellular vaccine combinations |
| JPWO2004113530A1 (ja) | 2003-06-18 | 2006-08-03 | 三菱化学株式会社 | ラベル化蛋白質合成用ポリヌクレオチド |
| RU2375076C2 (ru) | 2003-07-10 | 2009-12-10 | Цитос Биотехнологи Аг | Укомплектованные вирусоподобные частицы |
| JP2007507543A (ja) | 2003-10-06 | 2007-03-29 | セダーズ−シナイ メディカル センター | 樹状細胞治療によって誘導されるｔ細胞アネルギーを予防するためのｃｏｘ−２インヒビターの使用 |
| ES2378264T3 (es) | 2003-11-05 | 2012-04-10 | International Institute Of Cancer Immunology, Inc. | Péptido antigénico de unión a HLA-DR derivado de WT1 |
| CN101111258B (zh) | 2005-01-19 | 2011-07-06 | 大日本住友制药株式会社 | 稀释用乳化组合物及癌疫苗组合物 |
| JP4719876B2 (ja) * | 2005-04-04 | 2011-07-06 | 国立大学法人愛媛大学 | Ｈｌａクラスｉｉ拘束性ｗｔ１抗原ペプチド |
| CA2900087C (en) | 2005-10-17 | 2024-02-13 | Sloan Kettering Institute For Cancer Research | Wt1 hla class ii-binding peptides and compositions and methods comprising same |
| CN101336249A (zh) | 2005-11-30 | 2008-12-31 | 株式会社癌免疫研究所 | 新型肽化合物 |
| EP3117836A1 (en) | 2006-04-10 | 2017-01-18 | Sloan Kettering Institute For Cancer Research | Immunogenic wt-1 peptides and uses thereof |
| JP5427027B2 (ja) | 2006-05-03 | 2014-02-26 | ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・コロラド，ア・ボディー・コーポレイト | Ｃｄ４０アゴニスト抗体／ｉ型インターフェロン相乗性アジュバントの結合体、それを含む複合体、および細胞性免疫を強化する治療としてのその使用 |
| CA2652599C (en) | 2006-05-03 | 2019-09-24 | Ross Kedl | Cd40 agonist antibody/type1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity |
| GB0620894D0 (en) | 2006-10-20 | 2006-11-29 | Univ Southampton | Human immune therapies using a CD27 agonist alone or in combination with other immune modulators |
| US8653038B2 (en) | 2006-12-28 | 2014-02-18 | International Institute Of Cancer Immunology, Inc. | HLA-A* 1101-restricted WT1 peptide and pharmaceutical composition comprising the same |
| KR101183705B1 (ko) * | 2007-02-07 | 2012-09-17 | 사이단호진한다이비세이부쯔뵤우겐큐우카이 | 암의 치료제 |
| JP5463013B2 (ja) | 2007-06-19 | 2014-04-09 | 国立大学法人 岡山大学 | 軟骨マーカー |
| WO2009036246A2 (en) | 2007-09-14 | 2009-03-19 | Immunotope, Inc. | Immunogens that induce cytotoxic t-lymphocytes and their use in prevention, treatment, and diagnosis of cancer |
| US20100255020A1 (en) * | 2007-11-20 | 2010-10-07 | Nec Corporation | Method for inducing cytotoxic t-cells, cytotoxic t-cell inducers, and pharmaceutical compositions and vaccines employing them |
| TWI504407B (zh) * | 2007-12-05 | 2015-10-21 | Int Inst Cancer Immunology Inc | 癌疫苗組合物 |
| EP2337795A2 (en) | 2008-10-01 | 2011-06-29 | Dako Denmark A/S | Mhc multimers in cancer vaccines and immune monitoring |
| JP5520961B2 (ja) | 2008-11-28 | 2014-06-11 | エモリー ユニバーシティ | 感染症および腫瘍を処置するための方法 |
| BRPI1012560A2 (pt) | 2009-04-01 | 2016-07-26 | Genentech Inc | anticorpos anti-fcrh5 e imunoconjugados e métodos de uso |
| AR076349A1 (es) | 2009-04-23 | 2011-06-01 | Int Inst Cancer Immunology Inc | Peptido auxiliar del antigeno del cancer |
| KR101208587B1 (ko) | 2009-06-24 | 2012-12-06 | 여오영 | 하이드록시클로로퀸을 포함하는 항암 치료를 위한 국소 투여용 주사제 조성물 |
| US20130011424A1 (en) | 2010-03-09 | 2013-01-10 | Timur ARTEMEV | Polyepitope constructs and methods for their preparation and use |
| US20120213771A1 (en) | 2010-04-13 | 2012-08-23 | Celldex Therapeutics Inc. | Antibodies that bind human cd27 and uses thereof |
| KR101958753B1 (ko) | 2010-04-13 | 2019-03-15 | 셀덱스 쎄라퓨틱스, 인크. | 인간 ｃｄ27에 결합하는 항체 및 이의 용도 |
| JPWO2012026309A1 (ja) * | 2010-08-23 | 2013-10-28 | 公立大学法人横浜市立大学 | 抗ｐａｄ４抗体医薬の創成 |
| SG189287A1 (en) | 2010-10-05 | 2013-05-31 | Int Inst Cancer Immunology Inc | Method for activating helper t cell |
| EP2757373A4 (en) | 2011-09-14 | 2015-07-01 | Int Inst Cancer Immunology Inc | METHOD FOR MEASURING ANTI-WT1 ANTIBODIES |
| JP5704034B2 (ja) | 2011-09-26 | 2015-04-22 | コベルコ建機株式会社 | 建設機械の燃料供給装置及び同装置の組立方法 |
| CN103157108B (zh) | 2011-12-13 | 2016-01-20 | 宁云山 | 免疫调节剂组合物及其药物组合物和应用 |
| JP2015501839A (ja) | 2011-12-15 | 2015-01-19 | ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ | 受容体に対する親和性が増大した変異型ｌｉｇｈｔ分子を使用する癌療法のための方法および組成物 |
| JP5883668B2 (ja) | 2012-02-02 | 2016-03-15 | Hoya株式会社 | 分光データ採取システム、及び電子内視鏡システム |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| WO2014007266A1 (ja) | 2012-07-02 | 2014-01-09 | 大日本住友製薬株式会社 | 癌抗原ペプチド経皮剤 |
| CN103830211A (zh) | 2012-11-27 | 2014-06-04 | 上海曼克尔瑞生物医药技术有限公司 | 一种β-catenin蛋白抑制剂-姜黄素在肝癌治疗方面的应用 |
| US10206985B2 (en) | 2013-02-05 | 2019-02-19 | Nitto Denko Corporation | WT1 peptide cancer vaccine composition for mucosal administration |
| HUE050787T2 (hu) | 2013-02-26 | 2021-01-28 | Memorial Sloan Kettering Cancer Center | Immunterápiás készítmények és eljárások |
| JP6671956B2 (ja) * | 2013-03-29 | 2020-03-25 | 大日本住友製薬株式会社 | Ｅｒａｐ１によるトリミング機能をきっかけとしたコンジュゲートワクチン |
| RU2668560C2 (ru) * | 2013-03-29 | 2018-10-02 | Сумитомо Дайниппон Фарма Ко., Лтд. | Конъюгированная вакцина на основе пептида антигена wt1 |
| EP3030322A2 (en) | 2013-08-05 | 2016-06-15 | Cambridge Enterprise Limited | Inhibition of cxcr4 signaling in cancer immunotherapy |
| JP6329834B2 (ja) * | 2014-07-22 | 2018-05-23 | 株式会社アマダホールディングス | レーザ切断加工方法及び装置 |
| JP6515182B2 (ja) | 2015-05-20 | 2019-05-15 | 大日本住友製薬株式会社 | Ｗｔ１抗原ペプチドおよび免疫調節剤の併用 |
| WO2018101309A1 (ja) | 2016-11-30 | 2018-06-07 | 大日本住友製薬株式会社 | Ｗｔ１ヘルパーペプチド及びこれと癌抗原ペプチドコンジュゲート体との組合せ |
| WO2018181648A1 (ja) | 2017-03-30 | 2018-10-04 | 大日本住友製薬株式会社 | Ｗｔ１癌抗原ペプチドおよびこれを含むペプチドコンジュゲート体 |
-
2014
- 2014-03-28 RU RU2015146614A patent/RU2668560C2/ru active
- 2014-03-28 WO PCT/JP2014/059336 patent/WO2014157692A1/ja active Application Filing
- 2014-03-28 TR TR2018/16260T patent/TR201816260T4/tr unknown
- 2014-03-28 CA CA2907782A patent/CA2907782C/en active Active
- 2014-03-28 EP EP14775899.9A patent/EP2982681B8/en active Active
- 2014-03-28 JP JP2015508806A patent/JP5885885B2/ja active Active
- 2014-03-28 CN CN201480031047.2A patent/CN105308063B/zh active Active
- 2014-03-28 KR KR1020157030602A patent/KR102121638B1/ko active IP Right Grant
- 2014-03-28 EP EP18188307.5A patent/EP3461493A1/en active Pending
- 2014-03-28 MY MYPI2015703268A patent/MY171854A/en unknown
- 2014-03-28 ES ES14775899T patent/ES2691091T3/es active Active
- 2014-03-28 TW TW103111843A patent/TWI666026B/zh active
- 2014-03-28 NZ NZ71214814A patent/NZ712148A/en unknown
- 2014-03-28 AU AU2014244860A patent/AU2014244860B2/en active Active
- 2014-03-28 DK DK14775899.9T patent/DK2982681T3/en active
- 2014-03-28 MX MX2015013813A patent/MX364459B/es active IP Right Grant
- 2014-03-28 SG SG11201507883SA patent/SG11201507883SA/en unknown
- 2014-11-20 US US14/549,091 patent/US9181302B2/en active Active
-
2015
- 2015-05-07 US US14/706,772 patent/US9248173B2/en active Active
- 2015-09-10 IL IL241566A patent/IL241566B/en active IP Right Grant
- 2015-09-17 PH PH12015502180A patent/PH12015502180B1/en unknown
- 2015-12-30 US US14/984,763 patent/US20160114019A1/en not_active Abandoned
-
2016
- 2016-02-09 JP JP2016022512A patent/JP6495839B2/ja active Active
- 2016-07-19 HK HK16108516.0A patent/HK1220471A1/zh unknown
-
2018
- 2018-10-17 US US16/163,067 patent/US11759509B2/en active Active
- 2018-12-12 JP JP2018232776A patent/JP6847089B2/ja active Active
-
2020
- 2020-12-24 JP JP2020215273A patent/JP7248247B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276210B1 (en) | Mers-cov vaccine | |
| HK1220471A1 (zh) | 抗原肽綴合物疫苗 | |
| IL245744A0 (en) | Therapeutic peptides | |
| HK1219983A1 (zh) | 治療性肽 | |
| HK1214829A1 (zh) | 治療肽 | |
| GB201301085D0 (en) | Glycoconjugate Vaccine | |
| HRP20180452T1 (hr) | Peptidi | |
| ZA201602834B (en) | Salmonella conjugate vaccines | |
| GB201314411D0 (en) | Peptide conjugates | |
| HK1217206A1 (zh) | 疫苗 | |
| HK1211596A1 (en) | Peptide | |
| HK1211595A1 (en) | Peptide | |
| GB201315130D0 (en) | Peptides | |
| GB201320646D0 (en) | Vaccine | |
| GB201320421D0 (en) | Conjugated vaccine | |
| GB201315556D0 (en) | Vaccine | |
| GB201316660D0 (en) | Peptides | |
| GB201300381D0 (en) | Peptides |